Store
CAR-T Cell Therapy Market Review
Publication Date: December 19, 2019
Tags: Biopharma, CAR-T Cell Therapy, Immunoassay, Life Science, Oncology and Cancer, Pharma & Biopharma
Pages: 59
SKU: 19-099
CAR-T Cell Therapy Market Review provides an insightful examination of CAR-T therapy, a revolutionary form of immunotherapy harnessing the body’s T cells to target and eradicate cancer cells. This report delves into the technology behind CAR-T, its application in treating diseases like acute lymphoblastic leukemia, DLBCL B-cell lymphomas, and multiple myeloma.
Key Objectives and Questions Answered:
- Analysis of CAR-T market revenue growth and its sustainability
- Projections on market expansion and potential limitations
- Insights into global cancer burden and emerging market trends
Evaluation of major players and competition landscape
For further details and to purchase directly, please contact us.
Table of Contents
1: Executive Summary
Introduction
CAR-T Therapy Market Trends, Issues, and Recent Developments
CAR-T Therapy Market
Companies in the Market
2: CAR-T Cell Therapy Market
FDA-Approved CAR-T Therapies: Yescarta and Kymriah
- Yescarta
- Kymriah
- Table 2-1: FDA-Approved CAR-T Therapies
CAR-T Therapy Market Trends / Issues
- Global Cancer Burden
- Figure 2-1: Global Cancer Incidence Trends, 2010-2040
- Complexity of the CARs Manufacturing Process
- Diseases Treated with CAR-T
Recent Market Developments
- Study Shows Yescarta Increases Longevity
- CRS and Other Side Effects
- China CAR-T Competition
- Indian CAR-T Competition
- “Off-the-Shelf” CAR-T Therapies in Development
- A Competing Therapy in Development
Selected CAR-T Therapies in Development
-
- Table 2-2: Selected CAR-T Therapies in Development
- KTE-X19
- liso-cel
- C-CAR088
- IBI326 (Innovent) / CT103A (IASO BIO)
- bb21217
- MB-107
- ICTCAR014
- bb2121
- JNJ-682284528 (JNJ-4528)
- CT053
- MB-101 (IL-13Ra2)
- MB-108 (oncolytic virus C134)
- CYAD-01
- BAFF-R CAR-T
- MB-105 (PSCA)
- MB-102 (CD123)
- MB-103 (HER2)
- P-BCMA-101
- LCAR-B38M
- JCARH125
- MCARH171
- CYAD-101
- MB-106 (CD20)
- MB-104 (CS1)
- AMG 119
- ATA2271
- AUTO1
- AUTO3
CAR-T Market Analysis
-
- Figure 2-2: CAR-T Market, 2018-2024 ($millions)
- Market Share
- Figure 2-3: CAR-T Market Share, 2019 (%)
- Regional Breakout
- Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)
3: Companies in the Market
AbbVie, Inc.
- Company Summary
- Scripps Research Institute Deal
- Tyrosine Kinase Inhibitors Market
Autolus Therapeutics plc
Bellicum Pharmaceuticals, Inc.
bluebird bio, Inc.
- Company Summary
- bb2121
- bb21217
- bb2121
Bristol-Myers Squibb Company
- Company Summary
- BMS Acquires Celgene
- Monoclonal Antibodies Market
- Cancer Kinase Inhibitor Market
CARsgen Therapeutics
Celgene Corporation
- Company Summary
- Collaboration with Immatics Biotechnologies
- Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
- Celgene Buys JAK2 Inhibitor Maker
Cellectis, Inc.
- Pfizer
- Servier
Celyad
- CYAD-01
- CYAD-101
Gilead Sciences, Inc.
GlaxoSmithKline
Gracell Biotechnology
Immune Therapeutics
- CAR-T
Innovative Cellular Therapeutics
- ICTCAR014
Juno Therapeutics
- Selected CAR-T Therapies in Development
- Collaboration with Editas Medicine
Kite Pharma, Inc.
- KTE-X19
- Yescarta
Mustang Bio
Novartis International AG
- Company Summary
- Kymriah
- Intellia Therapeutics
- Other Company Activity
Pfizer, Inc.
Sorrento Therapeutics
ZIOPHARM Oncology, Inc.
Related products
The Worldwide Market for Clinical Laboratory Services, 9th Edition
June 25, 2024
Understanding the clinical laboratory market is crucial for effective business planning. The Worldwide Market for Clinical Laboratory Services, 9th Edition answers essential questions such as the size of the service market for clinical testing, the types of tests that are in demand, and the future trajectory of this market 2023-2028. It also identifies the companies…
Price range: $5,000.00 through $7,500.00
Cell and Gene Therapy Funding and Deals Analysis, 2021-2023
December 8, 2023
Explore the dynamic world of cell and gene therapy deal-making with Kalorama Information’s comprehensive report, Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023. This report tracks the deal-making activities in cell and gene therapy since 2021, providing insightful graphs of quarterly trends from 2021-2023 and detailing…
Price range: $5,000.00 through $7,500.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
Price range: $5,000.00 through $7,875.00
